BriaCell Therapeutics Corp. Announces Annual General Meeting on January 30, 2024
Ticker: BCTXZ · Form: DEF 14A · Filed: Jan 9, 2024 · CIK: 1610820
Complexity: simple
Sentiment: neutral
Topics: BriaCell Therapeutics, Annual Meeting, Proxy Statement, Financial Statements, Director Election
TL;DR
<b>BriaCell Therapeutics Corp. is holding its Annual General Meeting on January 30, 2024, to discuss financial statements, auditor appointment, and director elections.</b>
AI Summary
BriaCell Therapeutics Corp. (BCTXZ) filed a Proxy Statement (DEF 14A) with the SEC on January 9, 2024. BriaCell Therapeutics Corp. will hold its Annual General Meeting of Shareholders on January 30, 2024, at 10:00 a.m. Eastern Time. The meeting will include the receipt of audited financial statements for the years ended July 2023 and 2022. Shareholders will vote on the appointment of MNP LLP as the Company's auditors. The election of directors for the upcoming year will be a key agenda item. The proxy statement is dated December 27, 2023, and was first made available to shareholders on January 9, 2024.
Why It Matters
For investors and stakeholders tracking BriaCell Therapeutics Corp., this filing contains several important signals. Shareholders have the opportunity to vote on the company's financial health and future leadership. The meeting provides a formal platform for shareholder engagement on critical corporate governance matters.
Risk Assessment
Risk Level: low — BriaCell Therapeutics Corp. shows low risk based on this filing. The filing is a routine proxy statement for an annual general meeting and does not contain new financial or operational information that would indicate significant risk.
Analyst Insight
Shareholders should review the proxy materials to make informed voting decisions on financial statements, auditor appointments, and director elections.
Key Numbers
- January 30, 2024 — Annual General Meeting Date (Date of the Annual General Meeting of Shareholders.)
- 10:00 a.m. Eastern Time — Meeting Time (Time the Annual General Meeting will commence.)
- July 31, 2023 — Fiscal Year End (End of the fiscal year for the audited financial statements.)
- July 31, 2022 — Prior Fiscal Year End (End of the prior fiscal year for the audited financial statements.)
Key Players & Entities
- BriaCell Therapeutics Corp. (company) — Registrant and filer of the proxy statement.
- January 30, 2024 (date) — Date of the Annual General Meeting.
- MNP LLP (company) — Nominated as the company's auditors.
- July 2023 (date) — End of the most recent fiscal year for which financial statements will be received.
- July 2022 (date) — End of the prior fiscal year for which financial statements will be received.
- December 27, 2023 (date) — Date the proxy statement is dated.
- January 9, 2024 (date) — Date the proxy statement was first made available to shareholders.
FAQ
When did BriaCell Therapeutics Corp. file this DEF 14A?
BriaCell Therapeutics Corp. filed this Proxy Statement (DEF 14A) with the SEC on January 9, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by BriaCell Therapeutics Corp. (BCTXZ).
Where can I read the original DEF 14A filing from BriaCell Therapeutics Corp.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by BriaCell Therapeutics Corp..
What are the key takeaways from BriaCell Therapeutics Corp.'s DEF 14A?
BriaCell Therapeutics Corp. filed this DEF 14A on January 9, 2024. Key takeaways: BriaCell Therapeutics Corp. will hold its Annual General Meeting of Shareholders on January 30, 2024, at 10:00 a.m. Eastern Time.. The meeting will include the receipt of audited financial statements for the years ended July 2023 and 2022.. Shareholders will vote on the appointment of MNP LLP as the Company's auditors..
Is BriaCell Therapeutics Corp. a risky investment based on this filing?
Based on this DEF 14A, BriaCell Therapeutics Corp. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual general meeting and does not contain new financial or operational information that would indicate significant risk.
What should investors do after reading BriaCell Therapeutics Corp.'s DEF 14A?
Shareholders should review the proxy materials to make informed voting decisions on financial statements, auditor appointments, and director elections. The overall sentiment from this filing is neutral.
Risk Factors
- Receipt of Audited Financial Statements [low — regulatory]: Shareholders will review and receive the audited financial statements for the years ended July 2023 and 2022.
- Appointment of Auditors [low — operational]: Shareholders will vote on the appointment of MNP LLP as auditors and the authorization for the board to fix their remuneration.
- Election of Directors [low — operational]: Shareholders will elect directors for the forthcoming year based on nominations from the Board.
Key Dates
- 2024-01-30: Annual General Meeting — Shareholders will vote on key corporate matters including financial statements, auditor appointment, and director elections.
- 2024-01-09: Proxy Statement Availability — The proxy statement was first made available to shareholders.
- 2023-12-27: Proxy Statement Date — The official date of the proxy statement.
Filing Stats: 4,591 words · 18 min read · ~15 pages · Grade level 14.3 · Accepted 2024-01-09 16:05:36
Key Financial Figures
- $1.235 billion — ing growth company if we have more than $1.235 billion in annual revenues as of the end of a f
- $1.0 billion — ; SEC ”) or if we issue more than $1.0 billion of non-convertible debt over a three-ye
Filing Documents
- formdef14a.htm (DEF 14A) — 799KB
- formdef14-a_001.jpg (GRAPHIC) — 5KB
- formdef14-a_002.jpg (GRAPHIC) — 47KB
- formdef14-a_003.jpg (GRAPHIC) — 72KB
- formdef14-a_004.jpg (GRAPHIC) — 103KB
- formdef14-a_005.jpg (GRAPHIC) — 102KB
- formdef14-a_006.jpg (GRAPHIC) — 186KB
- proxy_001.jpg (GRAPHIC) — 302KB
- proxy_002.jpg (GRAPHIC) — 216KB
- 0001493152-24-001830.txt ( ) — 2224KB
Executive Compensation
Executive Compensation I-36 Director and Named Executive Officer Compensation I-36 Insider Trading and Reporting Policy I-42 Performance Graph I-43 Summary Compensation Table for 2023 I-43 Outstanding Equity Awards Table for 2023 Fiscal Year-End I-44 Incentive Plan Awards - Value Vested or Earned During the Year I-44 Pension Plan Benefits I-44 Termination and Change of Control Benefits I-44 Employment Agreements I-44 Liability Insurance of Directors and Officers I-45 Other Compensation I-45 DIRECTOR COMPENSATION I-46 Compensation of Directors I-46 Non-Employee Director Compensation for 2023 I-46 Other Compensation I-47 securities authorized for issuance under equity compensation plans I-47 Plan Maximum, Outstanding Securities Awarded and Remaining Securities Available for Grant I-47 INDEBTEDNESS OF DIRECTORS AND EXECUTIVE OFFICERS I-47 INTEREST OF INFORMED PERSONS IN MATERIAL TRANSACTIONS I-48 management conracts I-48
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT I-48 additional information I-49 board approval I-49 SCHEDULE “I” BOARD MANDATE I-50 I-4 General information about the annual general meeting and voting Proxy Materials Why am I receiving these materials? Management of the Company is using this proxy statement to solicit proxies for use at the Meeting to be held on January 30, 2024. The following proxy materials are being posted online and being mailed out to Shareholders: (1) the proxy statement; (2) the accompanying proxy card (“ Proxy Card ”); and (3) the Company’s Annual Report on Form 10-K for the year ended July 31, 2023 (including our audited annual consolidated financial statements of the Company for the fiscal year ended July 31, 2023, together with the notes thereto, and the independent auditor’s report thereon and the related management’s discussion and analysis). As a Shareholder, you are invited to attend the Meeting and are entitled and requested to vote on the business items described in this proxy This proxy statement is designed to assist you in voting your shares and includes information that we are required to provide under the rules of the U.S. Securities and Exchange Commission (the “ SEC ”) and applicable Canadian securities laws. These proxy materials are being sent to both registered and non-registered Shareholders. In some instances, the Company has distributed copies of the Notice, the proxy statement, the accompanying Proxy Card and the Company’s Annual Report on Form 10-K (collectively, the “ Meeting Materials ”) to clearing agencies, securities dealers, banks and trust companies, or their nominees (collectively “ Intermediaries ”, and each an “ Intermediary ”) for onward